| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9c8ee440d2758f894babeab7a24ca8cc |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2018-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d315aa18111a73711b3a0c1741fa7c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ed0787f99c2cce048cb94bf782c6b20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc33d14a2eec50db624a2dd7afde4075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b64693a38dda25873ea0f02ca0dd1f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94f9161cbfccad0f5a87e19550e0f901
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_085be919cbf99624535a2fb021d3048f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa9a8d7ec8ac79f247316c7dc9320504
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d863e9098b621ef39518de3e4df8c925 |
| publicationDate |
2018-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20180108550-A |
| titleOfInvention |
Monoclonal Antibodies Specific to Claudin 3 and 4, and The Use Thereof |
| abstract |
The present invention relates to antibodies against caludins 3 and 4 that can be used for the prevention or treatment of cancer. The antibody of the present invention is an antibody that specifically binds to cladins 3 and 4 overexpressed in cancer cells (particularly ovarian cancer cells) and has extremely low homology to CDR sequences of existing Claudin 3 or 4 target antibodies, There is the uniqueness of that sequence. The antibody of the present invention is very effective for preventing or treating cancer (particularly ovarian cancer) by killing cancer cells. |
| priorityDate |
2018-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |